Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome

  • Expert Opin Pharmacother. 2008 Jul;9(10):1787-96. doi: 10.1517/14656566.9.10.1787.
Martin C Michel  1
Affiliations
  • 1. University of Amsterdam, Department of Pharmacology and Pharmacotherapy, Academic Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands. [email protected]
PMID: 18570610 DOI: 10.1517/14656566.9.10.1787
Abstract

Background: Fesoterodine is a newly approved drug for the treatment of overactive bladder syndrome.

Objective: The aim of this study was to review the preclinical and clinical data on fesoterodine.

Methods: The study involved a search of the Medline database and the proceedings volumes of urological congresses.

Results/conclusions: Fesoterodine functions as an orally active prodrug that is converted to the active metabolite 5-hydroxymethyltolterodine by non-specific esterases. 5-Hydroxymethyltolterodine is a muscarinic receptor antagonist. Fesoterodine is primarily eliminated as inactive metabolites along with significant renal excretion as the unchanged active metabolite 5-hydroxymethyltolterodine. Fesoterodine is indicated for use at doses of 4 and 8 mg once daily. In clinical studies both doses of fesoterodine were consistently superior to placebo in improving the symptoms of overactive bladder syndrome, with 8 mg/day having significantly greater effects than 4 mg/day.

Products